Figure - PMC

Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2014 Mar 7.

Published in final edited form as: Brain Res. 2013 Jan 5;1499:1–11. doi: 10.1016/j.brainres.2012.12.030

Intrathecally catheterized subjects were baseline tested (Pre) as in Fig 1, and received an intrathecal injection of vehicle (Veh, 50% DMSO, 10 µl,), CC12 (500 nmol, 10µl), or naltrexone hydrochloride (Nal, 40 nmol, 10 µl). Subjects were re-tested (Post) 15 min later and immediately received a second injection of saline (Sal, 10 µl) or morphine sulfate (Mor, 20 µg, 10 µl). Tail flick (A) and hot plate (B) latencies (ordinate, sec, mean SEM, number of subjects in parentheses) were recorded at the time points indicated after the second injection (abscissa, min). **P<0.01 versus Veh/Sal; ^+,++ P<0.05, 0.01, respectively, versus Veh/Mor at the same time point. ^##P<0.01 for main effect of Nal in ANOVA. (B).

Intrathecally catheterized subjects were baseline tested (Pre) as in Fig 1, and received an intrathecal injection of vehicle (Veh, 50% DMSO, 10 µl,), CC12 (500 nmol, 10µl), or naltrexone hydrochloride (Nal, 40 nmol, 10 µl). Subjects were re-tested (Post) 15 min later and immediately received a second injection of saline (Sal, 10 µl) or morphine sulfate (Mor, 20 µg, 10 µl). Tail flick (A) and hot plate (B) latencies (ordinate, sec, mean SEM, number of subjects in parentheses) were recorded at the time points indicated after the second injection (abscissa, min). **P<0.01 versus Veh/Sal; ^+,++ P<0.05, 0.01, respectively, versus Veh/Mor at the same time point. ^##P<0.01 for main effect of Nal in ANOVA. (B).